The Department of Health made the submission, supported the evaluation, waived related cost recovery fees for itself, attended the PBAC meetings at which it has been considered and presumably participated in the discussion, wrote the outcome and managed the listing process. How is this not deeply problematic? …
A deeply problematic situation caused by officials making it up as they go
July 18, 2022 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
An argument that fails based on its own research findings
October 20, 2026 - - Latest News -
Be very careful about arguing for more pricing legislation, because you might just get it
October 20, 2026 - - Latest News -
Algorae signs two-part deal with Umedica to expand Australian portfolio
October 19, 2026 - - Latest News -
Novartis, Boehringer Ingelheim leaders join Medicines Australia board
October 19, 2026 - - Latest News -
The 'Dispatched' Podcast - Series 5. Ep.36
October 19, 2026 - - Podcast -
'If your doctor prescribes it, it should be covered,' pollster recommends as the key message
October 19, 2026 - - Latest News -
Cancer physicians now running communication skills workshops on how to discuss private pay
October 19, 2026 - - Latest News